Isothiocyanatostilbenes as novel c-Met inhibitors

The hepatocyte growth factor receptor (HGFR or c-Met) is a driver of multiple cancer subtypes. While there are several c-Met inhibitors in development, few have been approved for clinical use, warranting the need for continued research and development of c-Met targeting therapeutic modalities. The r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Alana L., Coleman, David T., Castore, Reneau F., Mohyeldin, Mohamed M., El Sayed, Khalid A., Cardelli, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747398/
https://www.ncbi.nlm.nih.gov/pubmed/26543230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747398/
https://www.ncbi.nlm.nih.gov/pubmed/26543230

Ejemplares similares